Previous Close | 0.1050 |
Open | 0.1000 |
Bid | 0.0990 x 3350000 |
Ask | 0.1000 x 10984500 |
Day's Range | 0.1000 - 0.1000 |
52 Week Range | 0.0650 - 0.1700 |
Volume | |
Avg. Volume | 1,445,779 |
Market Cap | 22.552M |
Beta (5Y Monthly) | 1.14 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.0200 |
Earnings Date | Feb 28, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
MELBOURNE, Australia, April 15, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our Chief Executive Officer, Steven Lydeamore together with our Chief Scientific Officer, Dr. Jerry Kanellos and Research & Development Manager, Dr. Joanne Casey will be hosting a Live Virtual Event on Tuesday, April 30 at 10am AEST / Monday, April 29 at 8pm EDT. TRAVELAN® BOUND FOR PHASE 3 CLINICAL TRIALSExp
Sales Highlights: Global FYTD Mar 2024 AUD$3.6 million up 154% on (prior comparative period) pcpMar 2024 Quarter AUD$1.3 million up 51% on pcp and 75% on last quarter Australia FYTD Mar 2024 AUD$2.8 million up 234% on pcpMar 2024 Quarter AUD$0.9 million up 66% on pcp and 99% on last quarter USA FYTD Mar 2024 AUD$0.8 million up 35% on pcpMar 2024 Quarter AUD$0.3 million up 7% on pcp and 18% on last quarterSales commenced on Walmart.com MELBOURNE, Australia, April 10, 2024 (GLOBE NEWSWIRE) -- Immu
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...